VRTX Stock Analysis: Buy, Sell, or Hold?
VRTX - Vertex Pharmaceuticals Inc
$440.05
3.78 (0.87%)
▲
5d:
+1.32%
30d:
-7.96%
90d:
-5.13%
BUY
MODERATE Confidence
Analysis Updated: Apr 13, 2026 12:00 AM ET
Earnings: May 04, 2026
20d
Smart Money Accumulation
VRTX is down 3.3% this week, but smart money is accumulating calls. Top strike: $560 2026-06-18 with 1,004 OI. Call ratio: 73% View Scanner →
Strength: 4.0/10
Get Alerted When VRTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: VRTX shows positive signals but monitor for confirmation. Market pricing in 2.8% decline. Moderate conviction.
💡 BUY OPPORTUNITY: VRTX shows positive signals but monitor for confirmation. Market pricing in 2.8% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$741.16
Based on 9.1% avg growth
INTRINSIC VALUE TODAY
$460.20
4.4% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 22.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: VRTX is currently trading at $440.05, which is considered slightly low relative to its 30-day fair value range of $437.81 to $470.34. The stock's valuation (Forward PE: 20.1) is in line with its historical norms (22.0). Remarkably, the market is currently pricing in an annual earnings decline of 2.8% over the next few years. This pessimistic expectation contrasts with the company's recent 32.9% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, VRTX is in a strong downtrend. Immediate support is located at $425.26, while resistance sits at $453.98.
Market Sentiment: VRTX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $548.45 (+24.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, VRTX is in a strong downtrend. Immediate support is located at $425.26, while resistance sits at $453.98.
Market Sentiment: VRTX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $548.45 (+24.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Fair Price Range
$437.81 -
$470.34
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
65.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 24.6% below Wall St target ($548.45)
Fair Price Analysis
30-Day Fair Range
$437.81 -
$470.34
Current vs Fair Value
SLIGHTLY LOW
Expected Move (7 Days)
±$22.44
(5.1%)
Support & Resistance Levels
Support Level
$425.26
Resistance Level
$453.98
Current Trend
Strong Downtrend
Technical data as of
Apr 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
20.13
Wall Street Target
$548.45
(+24.6%)
Revenue Growth (YoY)
9.5%
Earnings Growth (YoY)
32.9%
Profit Margin
32.9%
Valuation Discount vs History
-2.8% cheaper
PE vs Historical
20.1 vs 22.0
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-2.8%
(market-implied from PE analysis)
1-Year Target
$427.73
(-3%)
2-Year Target
$415.75
(-6%)
3-Year Target
$404.11
(-8%)
3-Yr Target (if PE normalizes)
(PE: 20→22)
$441.54
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.6, Growth: 14.2%)
$668.73
(+52%)
Base:
(SPY PE: 20.1, Growth: 14.2%)
$654.59
(+49%)
Bear:
(PE: 17.1, Growth: 14.2%)
$556.40
(+26%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (29x PE), but valuation improves significantly next year (20x PE) as earnings recover.
Trailing PE: 28.50 | Current EPS (TTM): $15.31
Bull Case
$685.06
(+56%)
Analyst growth 42.8%, PE expands to 31.4
Base Case
$622.78
(+42%)
Market implied 42.8%, PE stable at 28.5
Bear Case
$296.66
(-33%)
Severe decline -20.0%, PE contracts to 24.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 20.1 to 22.0
Stabilization Target:
$480.81
(+9.3%)
PE Expansion Potential:
+9.3%
Share & Embed Analysis
Last updated: April 13, 2026 6:43 PM ET
Data refreshes hourly during market hours. Next update: 7:43 PM
Data refreshes hourly during market hours. Next update: 7:43 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is VRTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
20
Sells
Net
INSIDERS SELLING
Recent Transactions
Joy Liu
SELL
978 shares
2026-04-01
Carmen Bozic
SELL
2329 shares
2026-03-13
Amit Sachdev
SELL
1846 shares
2026-02-25
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$449 | 60 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 61 BUY |
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$212 | 60 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 52 HOLD |
|
BEAM
Beam Therapeutics Inc |
STRONG BUY
17 analysts |
$51 | 57 HOLD |
Advanced VRTX Option Strategies
Professional options setups generated by AI based on today's VRTX price and gamma walls.
